Skip to main content

Table 3 Temozolomide specification and methods for measuring cell viability

From: Temozolomide sensitivity of malignant glioma cell lines – a systematic review assessing consistencies between in vitro studies

Characteristics N = 212
Temozolomide concentration (μM)
 Lower range (IQR)a 0 (0-10)
 Upper range (IQR)a 800 (250.0-1266)
 Unspecified 30 (14.2%)
Temozolomide exposure time
 <24 hours 8 (3.8%)
 24 hours 24 (11.3%)
 48 hours 34 (16.0%)
 72 hours 59 (27.8%)
 96 hours 15 (7.1%)
 >96 hours 25 (11.8%)
 Range of time 38 (17.9%)
 Unspecified 9 (4.2%)
Cell viability assay
 MTT 95 (44.8%)
 CCK-8 35 (16.5%)
 MTS 11 (5.2%)
 Trypan blue 11 (5.2%)
 Other 55 (25.9%)
 Unspecified 5 (2.4%)
Method for cell viability quantification
 Plate reader 124 (58.5%)
 Flow cytometry 13 (6.1%)
 Microscopy and manual counting 11 (5.2%)
 Microscopy and automated counting 3 (1.4%)
 Technique in a reference/manual 16 (7.5 %)
 Unspecified 45 (21.2%)
  1. aRange of temozolomide used to assess drug sensitivity was reported in 183 studies.
  2. IQR interquartile range, MTT 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyl-2H-tetrazolium bromide, CCK-8 Cell Counting Kit-8, MTS MTT with phenazine methosulfate